Analyst Research

Report Title Price
Provider: New Constructs, LLC
Provider: S&P Capital IQ Quantitative Report
Provider: Pechala's Reports
Provider: Reuters Investment Profile

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

DepoMed, Inc. Announces Submission Of New Drug Application For Serada

Tuesday, 31 Jul 2012 04:31pm EDT 

DepoMed, Inc. announced that it has submitted a New Drug Application (NDA) for Serada to the United States Food and Drug Administration. Serada is Depomed's extended release formulation of gabapentin in development for the treatment of menopausal hot flashes. 

Company Quote

-0.03 -0.23%
21 Apr 2014